The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study
Tóm tắt
This study aimed to determine the socioeconomic and clinical characteristics affecting health-related quality of life (HRQoL) in patients with psoriasis. A cross-sectional study was conducted between March and June 2015 using data obtained via an Internet-based survey completed by a psoriasis patient group in Korea. The survey included items regarding demographic, socioeconomic, and clinical characteristics and HRQoL. Patients’ HRQoL impairment was classified as severe if their Dermatology Life Quality Index Scores were ≥ 11. Factors influencing HRQoL impairment were identified using multivariate logistic regression analysis. Of the 299 respondents, 161 (53.8%) exhibited severe HRQoL impairment. The Dermatology Life Quality Index scores were significantly associated with gender, annual income, neck psoriasis, psoriasis-related resignation from work, and use of oral and herbal medications. The severity of HRQoL impairment in women was twice that observed in men (odds ratio [OR] = 2.00, 95% confidence interval (CI): 1.05–3.80). Patients with psoriasis on the neck exhibited significantly greater HRQoL impairment than those with psoriasis on other areas of their bodies (OR = 2.30, 95% CI: 1.20–4.43). With respect to the socioeconomic status, patients who earned > 40 million KRW (approximately 34,000 USD; high-income group) showed less HRQoL impairment compared with those who had lower incomes (OR = 0.47, 95% CI: 0.28–0.80). Patients with severe HRQoL impairment used oral (OR = 2.04, 95% CI: 1.20–3.44) and herbal (OR = 1.86, 95% CI: 1.04–3.34) medications more often relative to patients with less severe HRQoL impairment. HRQoL in patients with psoriasis was significantly associated with their demographic and socioeconomic characteristics and employment status. The presence of psoriasis on exposed areas of the body was significantly associated with patients’ HRQoL and employment status. Further research is required to evaluate the impact of psoriasis on patients’ productivity.
Tài liệu tham khảo
Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278–85.
Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485–96.
Health Insurance Review & Assessment Service. Healthcare Bigdata Hub. http://opendata.hira.or.kr/op/opc/olap3thDsInfo.do. Accessed 16 Nov 2017.
Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49:S57–61.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.
Pathirana D, Nast A, Ormerod AD, Reytan N, Saiag P, Smith CH, Spuls P, Rzany B. On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. J Eur Acad Dermatol Venereol. 2010;24:1458–67.
Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol. 1997;137:755–60.
Moos RH. Coping with physical illness II: new perspectives. New York: Plenum Medical Book Co; 1989.
Gupta MA, Gupta AK, Haberman HF. Psoriasis and psychiatry: an update. Gen Hosp Psychiatry. 1987;9:157–66.
Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges. 2007;5:566–74.
Fortune DG, Richards HL, Main CJ, Griffiths CEM. What patients with psoriasis believe about their condition. J Am Acad Dermatol. 1998;39:196–201.
Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43:281–5.
Feldman SR, Koo JY, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol. 2005;53:101–7.
Finlay AY, Khan GK. Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.
Loo WJ, Diba V, Chawla M, Finlay AY. Dermatology life quality index: influence of an illustrated version. Br J Dermatol. 2003;148:279–84.
Lewis V, Finlay AY. 10 years experience of the dermatology life quality index (DLQI). J Investig Dermatol Symp Proc. 2004;9:169–80.
Department of Dermatology. DLQI Different Language Versions. Cardiff University. http://sites.cardiff.ac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/dlqi-different-language-versions. Accessed 10 Oct 2017.
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125:659–64.
Fox FE, Rumsey N, Morris M. “Ur skin is the thing that everyone sees and you cant change it!”: exploring the appearance-related concerns of young people with psoriasis. Dev Neurorehabil. 2007;10:133–41.
Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol. 1989;20:53–63.
Geale K, Henriksson M, Schmitt-Egenolf M. How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden. Health Qual Life Outcomes. 2017;15:151.
Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol. 1990;123:751–6.
Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav. 2000;70:567–71.
Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D. Italian multipurpose psoriasis research on vital experiences study G: age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol. 2006;154:325–31.
Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsson B. Self-reported stress reactivity and psoriasis-related stress of Nordic psoriasis sufferers. J Eur Acad Dermatol Venereol. 2004;18:27–36.
Bougueon K, Misery L. Depression and psoriasis. Ann Dermatol Venereol. 2008;135(4):S254–8.
Matud MP. Gender differences in stress and coping styles. Personal Individ Differ. 2004;37:1401–15.
Mattila K, Leino M, Mustonen A, Koulu L, Tuominen R. Influence of psoriasis on work. Eur J Dermatol. 2013;23:208–11.
Chan B, Hales B, Shear N, Ho V, Lynde C, Poulin Y, Mittmann N. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg. 2009;13:192–7.
Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41:514–21.
Basinska MA, Drozdowska M. Emotional intelligence as an indicator of satisfaction with life of patients with psoriasis. Postepy Dermatol Alergol. 2013;30:365–72.
Gupta MA, Gupta AK. Quality of life of psoriasis patients. J Eur Acad Dermatol Venereol. 2000;14:241–2.
Farahnik B, Sharma D, Alban J, Sivamani RK. Topical botanical agents for the treatment of psoriasis: a systematic review. Am J Clin Dermatol. 2017;18:451–68.
Lee JY, Kang S, Park JS, Jo SJ. Prevalence of psoriasis in Korea: a population-based epidemiological study using the Korean National Health Insurance Database. Ann Dermatol. 2017;29:761–7.